1450 related articles for article (PubMed ID: 29301960)
1. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Miao D; Margolis CA; Gao W; Voss MH; Li W; Martini DJ; Norton C; Bossé D; Wankowicz SM; Cullen D; Horak C; Wind-Rotolo M; Tracy A; Giannakis M; Hodi FS; Drake CG; Ball MW; Allaf ME; Snyder A; Hellmann MD; Ho T; Motzer RJ; Signoretti S; Kaelin WG; Choueiri TK; Van Allen EM
Science; 2018 Feb; 359(6377):801-806. PubMed ID: 29301960
[TBL] [Abstract][Full Text] [Related]
2.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
3. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
[TBL] [Abstract][Full Text] [Related]
4. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapy in metastatic renal cell carcinoma.
Cho YH; Kim MS; Chung HS; Hwang EC
Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030
[TBL] [Abstract][Full Text] [Related]
6. Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus.
Colli LM; Jessop L; Myers TA; Camp SY; Machiela MJ; Choi J; Cunha R; Onabajo O; Mills GC; Schmid V; Brodie SA; Delattre O; Mole DR; Purdue MP; Yu K; Brown KM; Chanock SJ
Am J Hum Genet; 2021 Sep; 108(9):1590-1610. PubMed ID: 34390653
[TBL] [Abstract][Full Text] [Related]
7. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
Conway JR; Kofman E; Mo SS; Elmarakeby H; Van Allen E
Genome Med; 2018 Nov; 10(1):93. PubMed ID: 30497521
[TBL] [Abstract][Full Text] [Related]
8. Circadian lncRNA ADIRF-AS1 binds PBAF and regulates renal clear cell tumorigenesis.
Brooks R; Monzy J; Aaron B; Zhang X; Kossenkov A; Hayden J; Keeney F; Speicher DW; Zhang L; Dang CV
Cell Rep; 2022 Oct; 41(3):111514. PubMed ID: 36261012
[TBL] [Abstract][Full Text] [Related]
9. A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L; Naulaerts S; Govaerts J; Vanmeerbeek I; Sprooten J; Laureano RS; Dubroja N; Shankar G; Bosisio FM; Roussel E; Verbiest A; Finotello F; Ausserhofer M; Lambrechts D; Boeckx B; Wozniak A; Boon L; Kerkhofs J; Zucman-Rossi J; Albersen M; Baldewijns M; Beuselinck B; Garg AD
Nat Med; 2024 Jun; 30(6):1667-1679. PubMed ID: 38773341
[TBL] [Abstract][Full Text] [Related]
10. Genomic and immunologic correlates of LAG-3 expression in cancer.
Panda A; Rosenfeld JA; Singer EA; Bhanot G; Ganesan S
Oncoimmunology; 2020 May; 9(1):1756116. PubMed ID: 32923111
[TBL] [Abstract][Full Text] [Related]
11. YTHDF3 phase separation regulates HSPA13-dependent clear cell renal cell carcinoma development and immune evasion.
Dai C; Cao J; Tang Y; Jiang Y; Luo C; Zheng J
Cancer Sci; 2024 May; ():. PubMed ID: 38811341
[TBL] [Abstract][Full Text] [Related]
12. Kidney cancer.
Linehan WM; Rathmell WK
Urol Oncol; 2012; 30(6):948-51. PubMed ID: 23218074
[TBL] [Abstract][Full Text] [Related]
13. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states.
Nyman J; Denize T; Bakouny Z; Labaki C; Titchen BM; Bi K; Hari SN; Rosenthal J; Mehta N; Jiang B; Sharma B; Felt K; Umeton R; Braun DA; Rodig S; Choueiri TK; Signoretti S; Van Allen EM
Cell Rep Med; 2023 Sep; 4(9):101189. PubMed ID: 37729872
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of Clear-Cell Renal-Cell Carcinoma.
Grigolo S; Filgueira L
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893211
[TBL] [Abstract][Full Text] [Related]
15. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
16. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V; Fessler J; Bao R; Chongsuwat T; Zha Y; Alegre ML; Luke JJ; Gajewski TF
Science; 2018 Jan; 359(6371):104-108. PubMed ID: 29302014
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
18. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Nathanson T; Rizvi H; Creelan BC; Sanchez-Vega F; Ahuja A; Ni A; Novik JB; Mangarin LMB; Abu-Akeel M; Liu C; Sauter JL; Rekhtman N; Chang E; Callahan MK; Chaft JE; Voss MH; Tenet M; Li XM; Covello K; Renninger A; Vitazka P; Geese WJ; Borghaei H; Rudin CM; Antonia SJ; Swanton C; Hammerbacher J; Merghoub T; McGranahan N; Snyder A; Wolchok JD
Cancer Cell; 2018 May; 33(5):843-852.e4. PubMed ID: 29657128
[TBL] [Abstract][Full Text] [Related]
19. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
Miao D; Margolis CA; Vokes NI; Liu D; Taylor-Weiner A; Wankowicz SM; Adeegbe D; Keliher D; Schilling B; Tracy A; Manos M; Chau NG; Hanna GJ; Polak P; Rodig SJ; Signoretti S; Sholl LM; Engelman JA; Getz G; Jänne PA; Haddad RI; Choueiri TK; Barbie DA; Haq R; Awad MM; Schadendorf D; Hodi FS; Bellmunt J; Wong KK; Hammerman P; Van Allen EM
Nat Genet; 2018 Sep; 50(9):1271-1281. PubMed ID: 30150660
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Shukla SA; Bachireddy P; Schilling B; Galonska C; Zhan Q; Bango C; Langer R; Lee PC; Gusenleitner D; Keskin DB; Babadi M; Mohammad A; Gnirke A; Clement K; Cartun ZJ; Van Allen EM; Miao D; Huang Y; Snyder A; Merghoub T; Wolchok JD; Garraway LA; Meissner A; Weber JS; Hacohen N; Neuberg D; Potts PR; Murphy GF; Lian CG; Schadendorf D; Hodi FS; Wu CJ
Cell; 2018 Apr; 173(3):624-633.e8. PubMed ID: 29656892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
